A Randomized, Double-blinded, Open Label Study of the Efficacy and Safety of Cefcapene Pivoxil and Amoxicillin, Clavulanate in Acute Presumed Bacterial Rhinosinusitis.
- Author:
Ji Eun LEE
1
;
Doo Hee HAN
;
Tae Bin WON
;
Chae Seo RHEE
Author Information
1. Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea. csrhee@snu.ac.kr
- Publication Type:Comparative Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Sinusitis;
Bacterial infection;
Cefcapene pivoxil hydrochloride;
Amoxicillin potassium clavulanate combination;
Comparative study;
Double-blind method
- MeSH:
Amoxicillin;
Amoxicillin-Potassium Clavulanate Combination;
Bacterial Infections;
Cephalosporins;
Clavulanic Acid;
Compliance;
Demography;
Diarrhea;
Double-Blind Method;
Endoscopy;
Humans;
Sinusitis;
Treatment Outcome
- From:Clinical and Experimental Otorhinolaryngology
2011;4(2):83-87
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: Currently established first line therapy of acute (presumed bacterial) rhinosinusitis (ARS) consists of 10 to 14 days of oral amoxicillin or cephalosporins. This study compared the clinical efficacy and tolerance of cefcapene pivoxil (CP) and amoxicillin-clavulanate (AMC) in patients with ARS. METHODS: A randomized, open labeled, double-blinded trial of ARS patients over 15 years of age was performed. Patients diagnosed with ARS received paranasal sinus X-rays and nasal endoscopies and 2 weeks of either CP (150 mg, 3 times/ day) or AMC (625 mg, amoxicillin 500 mg, 3 times/day). All patients revisited the clinic on days 7, 14, and 28 for evaluation of changes in symptoms, endoscopy, and monitoring of any adverse reactions. Demographics, clinical characteristics and drug efficacy were also compared between the two groups. RESULTS: Among the 60 initially enrolled patients (CP 30, AMC 30), 5 patients in the CP group and 6 in the AMC group were excluded due to poor compliance. There were no significant differences in demographic data including age, sex, initial signs and symptoms, endoscopic and X-ray findings between the two groups. Rates of improvement after 2 weeks were 96% and 95.8% in the CP and AMC group, respectively. Sinus symptoms were changed significantly after 2 and 4 weeks, however, there was no difference between groups (P=0.41). The most common adverse reaction was gastrointestinal complication, diarrhea occurred in 1 patient in the CP group and 6 in the AMC group (P=0.04). CONCLUSION: CP and AMC were both effective in treating ARS. The difference of treatment outcome was not found between the two groups, however, gastrointestinal complications were less prevalent in the CP group.
